Robert W. Baird Cuts Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $652.00
Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) had its price objective lowered by Robert W. Baird from $759.00 to $652.00 in a report issued on Friday,Benzinga reports. The firm presently has a “neutral” rating on the biopharmaceutical company’s stock. Robert W. Baird’s price objective points to a potential upside of 8.19% from the stock’s current […]
Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) had its price objective lowered by Robert W. Baird from $759.00 to $652.00 in a report issued on Friday,Benzinga reports. The firm presently has a “neutral” rating on the biopharmaceutical company’s stock. Robert W. Baird’s price objective points to a potential upside of 8.19% from the stock’s current […]
